Skip to main content

Table 3 Association between breast cancer median CXCL13 content and distant disease-fee survival in four molecular subtypes

From: Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population

Subtype

Univariable modelHR (95% CI)

P

Multivariable modelHR (95% CI)

P

Luminal A-like

0.60 (0.27–1.34)

0.214

0.57 (0.24–1.34)

0.194

Luminal B-like

0.59 (0.27–1.28)

0.180

0.49 (0.20–1.17)

0.109

Triple-negative

0.42 (0.22–0.83)

0.012

0.39 (0.19–0.79)

0.009

HER2-positive

0.78 (0.43–1.42)

0.421

0.75 (0.40–1.41)

0.372

  1. Abbreviations: CI confidence interval, HR hazard ratio, HER2 human epidermal growth factor receptor 2